In head and neck cancer, CDK2AP1 inhibits CDK2/CyclinE activity, while under normal conditions CDK2/CyclinE can phosphorylate Retinoblastoma Protein (Rb), release E2F, and then transcribe the required components of the cell, subsequently going through the G1/S phase transition (Figueiredo et al., 2005). The gene discussed is CDK2; the disease is head and neck cancer.